Cencora (NYSE:COR - Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 17.650-17.900 for the period, compared to the consensus earnings per share estimate of 17.600. The company issued revenue guidance of $334.2 billion-$340.6 billion, compared to the consensus revenue estimate of $345.9 billion.
Cencora Trading Up 0.7%
NYSE:COR opened at $305.89 on Wednesday. Cencora has a 12-month low of $271.00 and a 12-month high of $377.54. The firm has a market capitalization of $59.50 billion, a P/E ratio of 36.77, a P/E/G ratio of 1.42 and a beta of 0.64. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The business has a 50 day simple moving average of $332.27 and a 200 day simple moving average of $343.21.
Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.80 by ($0.05). Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts predict that Cencora will post 17.58 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the company. Barclays boosted their price target on Cencora from $400.00 to $425.00 and gave the stock an "overweight" rating in a research report on Friday, February 13th. Leerink Partners reiterated an "outperform" rating on shares of Cencora in a research report on Tuesday, March 17th. JPMorgan Chase & Co. boosted their price target on Cencora from $417.00 to $419.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 10th. Morgan Stanley set a $380.00 price target on Cencora in a research report on Tuesday, March 17th. Finally, Wells Fargo & Company boosted their price target on Cencora from $405.00 to $429.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 10th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and a consensus target price of $398.17.
View Our Latest Report on COR
Institutional Investors Weigh In On Cencora
Institutional investors and hedge funds have recently modified their holdings of the stock. Kemnay Advisory Services Inc. acquired a new stake in shares of Cencora during the fourth quarter worth $25,000. Motiv8 Investments LLC acquired a new stake in shares of Cencora during the fourth quarter worth $29,000. Turning Point Benefit Group Inc. acquired a new stake in shares of Cencora during the third quarter worth $74,000. DV Equities LLC acquired a new stake in shares of Cencora during the fourth quarter worth $91,000. Finally, Greenline Wealth Management LLC acquired a new position in Cencora during the fourth quarter valued at $109,000. 97.52% of the stock is owned by institutional investors and hedge funds.
About Cencora
(
Get Free Report)
Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
